display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced - esophageal cancer (mEC)
mEC - 1st line (L1)
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus SoC KEYNOTE-590

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons